Joint Formulary & PAD

Co-dydramol 30/500 - Pain

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
Fixed combinations are less preferred. The MHRA advises when prescribing dihydrocodeine with paracetamol, the tablet strength and dose must be clearly indicated

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Co-dydramol 30/500
Indication :
Pain
Group Name :
Keywords :
Dihydrocodeine with paracetamol, non-opioid analgesia, analgesics, compound analgesics
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0